Literature DB >> 18165031

A simple, cost-effective screening protocol to rule out periprosthetic infection.

Matthew S Austin1, Elie Ghanem, Ashish Joshi, Adam Lindsay, Javad Parvizi.   

Abstract

The differential diagnosis of pain after total knee arthroplasty includes infection. Effective screening tools should have high sensitivity and are cost-effective. We evaluated 296 patients who underwent total knee revision at our institution. One hundred sixteen patients (39%) were classified as infected and 180 patients (61%) were considered noninfected. The mean erythrocyte sedimentation rate (ESR) and C-reactive protein (CRP) of the infected patients were 85 mm/h and 110 mg/L, respectively. The mean ESR and CRP of the noninfected patients were 22 mm/h and 7 mg/L, respectively. Five patients (4%) in the infected group had both normal ESR and CRP. Infection was suspected in all 5 patients, and an organism was cultured in 4 of the 5 cases. Erythrocyte sedimentation rate and CRP, when used in combination, serve as a useful screening tool in patients with a painful total knee arthroplasty.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18165031     DOI: 10.1016/j.arth.2007.09.005

Source DB:  PubMed          Journal:  J Arthroplasty        ISSN: 0883-5403            Impact factor:   4.757


  33 in total

1.  Serological markers can lead to false negative diagnoses of periprosthetic infections following total knee arthroplasty.

Authors:  Aaron J Johnson; Michael G Zywiel; Alex Stroh; David R Marker; Michael A Mont
Journal:  Int Orthop       Date:  2010-12-23       Impact factor: 3.075

Review 2.  [Classification of prosthetic loosening and determination of wear particles].

Authors:  M Otto
Journal:  Pathologe       Date:  2008-11       Impact factor: 1.011

3.  Diagnosis of infected total knee: findings of a multicenter database.

Authors:  Javad Parvizi; Elie Ghanem; Peter Sharkey; Ajay Aggarwal; R Stephen J Burnett; Robert L Barrack
Journal:  Clin Orthop Relat Res       Date:  2008-09-10       Impact factor: 4.176

4.  [Aseptic loosening of total ankle replacement and conversion to ankle arthrodesis].

Authors:  M D Wimmer; M Hettchen; M M Ploeger; B Hintermann; D C Wirtz; A Barg
Journal:  Oper Orthop Traumatol       Date:  2017-04-25       Impact factor: 1.154

5.  The role of MRI in musculoskeletal practice: a clinical perspective.

Authors:  Gail Dean Deyle
Journal:  J Man Manip Ther       Date:  2011-08

6.  Diagnostic accuracy of interleukin-6 and procalcitonin in patients with periprosthetic joint infection: a systematic review and meta-analysis.

Authors:  Jung-Ro Yoon; Se-Hyun Yang; Young-Soo Shin
Journal:  Int Orthop       Date:  2018-01-02       Impact factor: 3.075

7.  Increasing financial burden of revision total knee arthroplasty.

Authors:  Kayode O Oduwole; Diarmuid C Molony; Ray J Walls; Simi P Bashir; Kevin J Mulhall
Journal:  Knee Surg Sports Traumatol Arthrosc       Date:  2010-02-11       Impact factor: 4.342

8.  C-reactive protein (CRP) in different types of minimally invasive knee arthroplasty.

Authors:  Emmanuel Thienpont; Irina Grosu; Sylvie Jonckheere; Jean Cyr Yombi
Journal:  Knee Surg Sports Traumatol Arthrosc       Date:  2012-12-30       Impact factor: 4.342

9.  C-reactive protein, erythrocyte sedimentation rate and orthopedic implant infection.

Authors:  Kerryl E Piper; Marta Fernandez-Sampedro; Kathryn E Steckelberg; Jayawant N Mandrekar; Melissa J Karau; James M Steckelberg; Elie F Berbari; Douglas R Osmon; Arlen D Hanssen; David G Lewallen; Robert H Cofield; John W Sperling; Joaquin Sanchez-Sotelo; Paul M Huddleston; Mark B Dekutoski; Michael Yaszemski; Bradford Currier; Robin Patel
Journal:  PLoS One       Date:  2010-02-22       Impact factor: 3.240

10.  Tibial tubercle osteotomy or quadriceps snip in two-stage revision for prosthetic knee infection? A randomized prospective study.

Authors:  Danilo Bruni; Francesco Iacono; Bharat Sharma; Stefano Zaffagnini; Maurilio Marcacci
Journal:  Clin Orthop Relat Res       Date:  2013-01-03       Impact factor: 4.176

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.